Bolt Biotherapeutics, Inc. (BOLT)
4.91
-0.15
(-2.96%)
USD |
NASDAQ |
Nov 20, 16:00
4.91
0.00 (0.00%)
After-Hours: 20:00
Bolt Biotherapeutics Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.32K% |
| March 31, 2026 | -680.8% |
| December 31, 2025 | 89.80% |
| September 30, 2025 | 86.63% |
| June 30, 2025 | 80.76% |
| March 31, 2025 | 67.35% |
| December 31, 2024 | |
| September 30, 2024 | 61.44% |
| June 30, 2024 | 64.16% |
| March 31, 2024 | 91.32% |
| December 31, 2023 | 76.21% |
| September 30, 2023 | 81.72% |
| June 30, 2023 | 17.03% |
| March 31, 2023 | 35.05% |
| Date | Value |
|---|---|
| December 31, 2022 | 17.29% |
| September 30, 2022 | 46.92% |
| June 30, 2022 | 0.00% |
| March 31, 2022 | -87.95% |
| December 31, 2021 | -78.15% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Caribou Biosciences, Inc. | 63.29% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | 39.18% |
| Sarepta Therapeutics, Inc. | 49.02% |
| Anixa Biosciences, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -130.6% |
| Return on Assets | -51.74% |
| Return on Invested Capital | -61.65% |
| Return on Net Operating Assets | -134.5% |